Abstract

  The 2019-novel coronavirus (CoV) is a major source of disaster in the 21st century. However, the lack of specific drugs to prevent an attack is a major need at this current point of time. COVID-19 is a disease occurred due to corona virus. In this regard, I have conducted a systematic review to identify possible treatment of corona virus (CoV). The search based on it including herbal and allopathic drugs as no any vaccines and medicines are available to treat COVID-19. Till 22nd September 2020, the numbers of patients currently infected are 31,174,627 from which 962,613 people were died. Thus, this review provides beneficial treatment in current situation. Starting from 2005 to 2020 some major studies have been done to treat this corona virus including traditional Chinese medicines. First time this disease was observed in chine in 2002, so after 2003 the research was started on corona virus, currently known as COVID-19.

Keywords: Corona Virus; COVD-19; Allopathic Drugs; Herbal Medicines

References

1. Liu W., et al. “Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV”. Chembiochem5 (2020): 7030-738.
2. MW R., et al. “Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) In vitro”. Cell Research (2020).
3. Kit-Man L., et al. “Immunomodulatory and anti-SARS activities of Houttuynia cordata”. Journal of Ethnopharmacology 118 (2008): 79-85.
4. Shi-you L., et al. “Identification of natural compounds with antiviral activities against SARS-associated coronavirus”. Antiviral Research 67 (2005): 18-23.
5. Cheng-Wen L., et al. “Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds”. Antiviral Research 68 (2005): 36-42.
6. Cheng-Wei Y., et al. “Identification of phenanthroindolizines and phenanthroquinolizidines as novel potent anti-coronaviral agents for porcine enteropathogenic coronavirus transmissible gastroenteritis virus and human severe acute respiratory syndrome coronavirus”. Antiviral Research 88 (2010): 160-168.
7. Young Bae R., et al. “Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition”. Bioorganic and Medicinal Chemistry 18 (2010): 7940-7947.
8. Mi-Sun Y., et al. “Identification of myricetin and Scrutellare as novel chemical inhibitors of the SARS coronavirus helicase nsP13”. Bioorganic and Medicinal Chemistry Letters 22 (2012): 4049-4054.
9. Deng-hai Z., et al. “In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus”. Journal of Integrative Medicine 18 (2020): 152-158.
10. Sophie Alexandra B., et al. “Teicoplanin: an alternative drug for the treatment of COVID-19”. International Journal of Antimicrobial Agents 18 (2020): 105944.
11. Didier R., et al. “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”. International Journal of Antimicrobial Agents1 (2020): 105949.
12. Lisi D., et al. “Arbidol combined with LPV/r verses LPV/r alone against corona virus disease 2019: A Retrospective cohort study”. Journal of Infection1 (2020): e1-e5.

Citation

Citation: Janani Ravi., et al. “Conflicts Between Evidence and Clinical Practice-current Scenario in Paediatric Neuro Rehabilitation.".Acta Scientific Pharmacology 2.1 (2020): 18-19.

Copyright

Copyright: © 2020 Janani Ravi., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.